Treatment Outcomes and Prognostic Factors in 40 Patients with Primary Effusion Lymphoma
Krithika Shanmugasundaram(National Cancer Institute), Kathryn Lurain(The Ohio State University), Denise Whitby(Frederick National Laboratory for Cancer Research), Ralph Mangusan(AIDS United), Thomas S. Uldrick(Regeneron (United States)), Richard F. Little(Dana-Farber Cancer Institute), Vickie Marshall(Leidos (United States)), Mark N. Polizzotto(AIDS United), Anaida Widell(AIDS United), Ramya Ramaswami(National Cancer Institute), Elaine S. Jaffe(National Cancer Institute), Stefania Pittaluga(New York University), Hao‐Wei Wang(Fu Jen Catholic University), Robert Yarchoan(National Cancer Institute)
Cited by 7
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k